Cosela (trilaciclib) is a new FDA-approved oncology therapy manufactured by G1 Therapeutics
… New G1 Therapy Cosela (trilaciclib) is an important new therapy for oncology …

G1 Therapeutics’ Cosela (trilaciclib) Earns FDA Oncology Approval

New oncology therapy indicated for use in the treatment of small cell lung cancer

John G. Baresky

Cosela is a unique and advanced cancer therapy

Cosela is the first and only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small-cell lung cancer being treated with chemotherapy.

Cosela trilaciclib is an important new drug to help minimize the impact of chemotherapy side effects on cancer patients
Cosela trilaciclib is an important new drug to help minimize the impact of chemotherapy side effects on cancer patients
… Cosela is a new therapy that will be valued by cancer patients and oncologists …

Chemotherapy can have harmful side-effects that Cosela may help prevent in some patients

Chemotherapy drugs are intended to kill cancer cells but may also damage normal, healthy tissues as well. Bone marrow is particularly susceptible to the unintended damaging effects of chemotherapy. The bone marrow produces red blood cells, white blood cells and platelets that are necessary to transport oxygen, fight infection and stop bleeding.

G1 Therapeutics is partnering with Boehringer Ingelheim to fully commercialize Cosela and propel its market access

G1 Therapeutics is collaborating with Boehringer Ingelheim to market Cosela in the United States. Boehringer Ingelheim is an ideal partner for G1 Therapeutics to launch Cosela as it is seeking to expand its business presence in the oncology healthcare sector. Cosela’s success at launch and onward will definitely benefit from Boehringer Ingelheim’s market access strategy savvy.

G1 Therapeutics has further cancer therapy innovations underway

The company is exploring further uses for Cosela. This includes conducting clinical trials and other evaluations that may lead to bladder, breast and other lung cancer indications. Another pipeline candidate G1 is working on is rintodestrant. This product is intended to be taken orally and is a selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer.

Lerociclib is a G1 Therapeutics product licensed to other biotech companies

G1 Therapeutics has developed a compound intended for use in cancer treatment, Lerociclib (a differentiated oral CDK4/6 inhibitor), that has been licensed to EQRx for the United States, Europe, Japan and other territories; Genor Biopharma has the license for it in the Asia-Pacific region.

G1 Therapeutics is a compact and innovative biopharmaceutical enterprise

Founded in 2008, G1 Therapeutics (NASDAQ: GTHX) is based in Research Triangle Park, North Carolina. Its pharmaceutical business model is aligned with the development and commercialization of new small molecule therapies for use in oncology. Congratulations to G1 Therapeutics on the launch of their first new oncology therapy Cosela!

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/